| HGNC Family | Non-coding RNAs |
| Name | microRNA 492 |
| Description | microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop. [provided by RefSeq, Sep 2009] |
| Summary |
{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nmiR‐492 is emerging as a multifaceted post‐transcriptional regulator whose expression and activity impact diverse cellular processes, particularly in cancer. In breast cancer, miR‐492 is overexpressed and promotes cell proliferation and anchorage‐independent growth through direct targeting and subsequent downregulation of the tumor suppressor SOX7."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": " In hepatoblastoma, miR‐492 can be generated within the coding region of keratin 19, with elevated levels correlating with metastatic tumors."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": " In prostate cancer, miR‐492 modulates the concentration of the transcription factor MZF‐1, affecting iron metabolism through regulation of ferroportin expression"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "4"}]}, {"type": "t", "text": ", while investigations in ovarian cancer and prostate cancer are underway to further define its oncogenic potential."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "5"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nBeyond oncogenesis, miR‐492 also plays significant roles in modulating treatment responses and cellular signaling in other contexts. In colon cancer, lower levels of miR‐492 are associated with oxaliplatin resistance, and its exogenous expression re‐sensitizes resistant cells via direct targeting of CD147."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "7"}]}, {"type": "t", "text": " In high‐glucose conditions relevant to atherosclerosis, reduced miR‐492 results in elevated resistin expression, contributing to insulin resistance and endothelial dysfunction"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "8"}]}, {"type": "t", "text": ", and in human umbilical vein endothelial cells, miR‐492 overexpression suppresses proliferation, migration, and tube formation by indirectly downregulating eNOS and VEGF."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "9"}]}, {"type": "t", "text": " In cervical squamous cell carcinoma, higher miR‐492 levels are linked to enhanced sensitivity to chemoradiotherapy and are associated with pelvic lymph node metastasis via regulation of TIMP2 and MMP10."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "10"}]}, {"type": "t", "text": " Additionally, in retinoblastoma, miR‐492 is upregulated and directly targets LATS2, thus promoting malignant cell behaviors"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "11"}]}, {"type": "t", "text": ", while in osteosarcoma and clear cell renal cell carcinoma its expression is diminished, and restoration of miR‐492 inhibits tumor cell proliferation and invasion."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "12"}]}, {"type": "t", "text": " Moreover, a single‐nucleotide polymorphism within miR‐492 (rs2289030) has been associated with favorable prognosis in hepatocellular carcinoma"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "14"}]}, {"type": "t", "text": "and with susceptibility to Hirschsprung disease"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "15"}]}, {"type": "t", "text": ", and in psoriasis, variations within its binding site affect the suppression of BSG expression."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "16"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nRegulatory networks modulating miR‐492 activity further underscore its functional versatility. In renal cell carcinoma, the circular RNA circ_0001368 acts as an endogenous sponge for miR‐492, thereby releasing the suppression on LYVE1 and curbing tumor progression."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "17"}]}, {"type": "t", "text": " In gastric cancer, emerging evidence suggests that the miR‐492/CD147 axis contributes to chemoresistance and metastatic progression, positioning miR‐492 as a potential therapeutic target."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "18"}]}, {"type": "t", "text": " Finally, an exploratory study has also considered the role of miR‐492 in the post‐transcriptional regulation of the OK blood group antigen on red blood cells."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "19"}]}, {"type": "t", "text": " Collectively, these studies illustrate that miR‐492 functions in a context‐dependent manner to either promote or suppress tumorigenesis and modulate cellular responses to environmental and therapeutic stimuli.\n"}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Fei Shen, Wen-Song Cai, Zhe Feng, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MiR-492 contributes to cell proliferation and cell cycle of human breast cancer cells by suppressing SOX7 expression."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Tumour Biol (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s13277-014-2794-z"}], "href": "https://doi.org/10.1007/s13277-014-2794-z"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "25407488"}], "href": "https://pubmed.ncbi.nlm.nih.gov/25407488"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Julia von Frowein, Philipp Pagel, Roland Kappler, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Hepatology (2011)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/hep.24125"}], "href": "https://doi.org/10.1002/hep.24125"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "21319197"}], "href": "https://pubmed.ncbi.nlm.nih.gov/21319197"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Julia von Frowein, Stefanie M Hauck, Roland Kappler, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MiR-492 regulates metastatic properties of hepatoblastoma via CD44."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Liver Int (2018)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1111/liv.13687"}], "href": "https://doi.org/10.1111/liv.13687"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "29314711"}], "href": "https://pubmed.ncbi.nlm.nih.gov/29314711"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Y Chen, Z Zhang, K Yang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Oncogene (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/onc.2014.310"}], "href": "https://doi.org/10.1038/onc.2014.310"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "25284586"}], "href": "https://pubmed.ncbi.nlm.nih.gov/25284586"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "Zhong Wang, Yihua Liu, Min Wang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Effects of miR-492 on migration, invasion, EMT and prognosis in ovarian cancer by targeting SOX7."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J BUON (2020)"}]}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32521870"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32521870"}]}, {"type": "r", "ref": 6, "children": [{"type": "t", "text": "L-P Shi, M Liang, F-F Li, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MiR-492 exerts tumor-promoting function in prostate cancer through repressing SOCS2 expression."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Eur Rev Med Pharmacol Sci (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.26355/eurrev_201902_16986"}], "href": "https://doi.org/10.26355/eurrev_201902_16986"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30779065"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30779065"}]}, {"type": "r", "ref": 7, "children": [{"type": "t", "text": "Lipan Peng, Huaqiang Zhu, Jinshen Wang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MiR-492 is functionally involved in Oxaliplatin resistance in colon cancer cells LS174T via its regulating the expression of CD147."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Mol Cell Biochem (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s11010-015-2397-z"}], "href": "https://doi.org/10.1007/s11010-015-2397-z"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "25862460"}], "href": "https://pubmed.ncbi.nlm.nih.gov/25862460"}]}, {"type": "r", "ref": 8, "children": [{"type": "t", "text": "Cai Ying, Liu Sui-Xin, Xie Kang-Ling, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MicroRNA-492 reverses high glucose-induced insulin resistance in HUVEC cells through targeting resistin."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Mol Cell Biochem (2014)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s11010-014-1993-7"}], "href": "https://doi.org/10.1007/s11010-014-1993-7"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "24526524"}], "href": "https://pubmed.ncbi.nlm.nih.gov/24526524"}]}, {"type": "r", "ref": 9, "children": [{"type": "t", "text": "Francesca Patella, Eleonora Leucci, Monica Evangelista, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MiR-492 impairs the angiogenic potential of endothelial cells."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Cell Mol Med (2013)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1111/jcmm.12085"}], "href": "https://doi.org/10.1111/jcmm.12085"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "23802567"}], "href": "https://pubmed.ncbi.nlm.nih.gov/23802567"}]}, {"type": "r", "ref": 10, "children": [{"type": "t", "text": "Mei Liu, Jusheng An, Manni Huang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MicroRNA-492 overexpression involves in cell proliferation, migration, and radiotherapy response of cervical squamous cell carcinomas."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Mol Carcinog (2018)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/mc.22717"}], "href": "https://doi.org/10.1002/mc.22717"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "28802022"}], "href": "https://pubmed.ncbi.nlm.nih.gov/28802022"}]}, {"type": "r", "ref": 11, "children": [{"type": "t", "text": "Zhiqun Sun, Aimei Zhang, Liming Zhang "}, {"type": "b", "children": [{"type": "t", "text": "Inhibition of microRNA‑492 attenuates cell proliferation and invasion in retinoblastoma via directly targeting LATS2."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Mol Med Rep (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3892/mmr.2018.9784"}], "href": "https://doi.org/10.3892/mmr.2018.9784"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30592270"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30592270"}]}, {"type": "r", "ref": 12, "children": [{"type": "t", "text": "Xuanhe Song, Yaoping Xie, Yang Liu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MicroRNA-492 overexpression exerts suppressive effects on the progression of osteosarcoma by targeting PAK7."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Int J Mol Med (2017)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3892/ijmm.2017.3046"}], "href": "https://doi.org/10.3892/ijmm.2017.3046"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "28677719"}], "href": "https://pubmed.ncbi.nlm.nih.gov/28677719"}]}, {"type": "r", "ref": 13, "children": [{"type": "t", "text": "Aibing Wu, Kunpeng Wu, Mingchun Li, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Upregulation of microRNA-492 induced by epigenetic drug treatment inhibits the malignant phenotype of clear cell renal cell carcinoma in vitro."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Mol Med Rep (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3892/mmr.2015.3550"}], "href": "https://doi.org/10.3892/mmr.2015.3550"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "25815441"}], "href": "https://pubmed.ncbi.nlm.nih.gov/25815441"}]}, {"type": "r", "ref": 14, "children": [{"type": "t", "text": "Guopeng Yu, Qianyi Xiao, Xiao-Pin Ma, et al. "}, {"type": "b", "children": [{"type": "t", "text": "miR-492G>C polymorphism (rs2289030) is associated with overall survival of hepatocellular carcinoma patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Tumour Biol (2016)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s13277-015-4752-9"}], "href": "https://doi.org/10.1007/s13277-015-4752-9"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "26753964"}], "href": "https://pubmed.ncbi.nlm.nih.gov/26753964"}]}, {"type": "r", "ref": 15, "children": [{"type": "t", "text": "Yi Zheng, Yanqing Liu, Mi Wang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Association between "}, {"type": "a", "children": [{"type": "t", "text": "i"}], "href": "i"}, {"type": "t", "text": "miR-492"}, {"type": "a", "children": [{"type": "t", "text": "/i"}], "href": "/i"}, {"type": "t", "text": " rs2289030 G>C and susceptibility to Hirschsprung disease in southern Chinese children."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Int Med Res (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1177/0300060520961680"}], "href": "https://doi.org/10.1177/0300060520961680"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "33103535"}], "href": "https://pubmed.ncbi.nlm.nih.gov/33103535"}]}, {"type": "r", "ref": 16, "children": [{"type": "t", "text": "Li-Sha Wu, Fang-Fang Li, Liang-Dan Sun, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A miRNA-492 binding-site polymorphism in BSG (basigin) confers risk to psoriasis in central south Chinese population."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Hum Genet (2011)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s00439-011-1026-5"}], "href": "https://doi.org/10.1007/s00439-011-1026-5"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "21655935"}], "href": "https://pubmed.ncbi.nlm.nih.gov/21655935"}]}, {"type": "r", "ref": 17, "children": [{"type": "t", "text": "Yu-Han Wang, Xiao-Hui Huang, Yan-Mei Yang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Mysm1 epigenetically regulates the immunomodulatory function of adipose-derived stem cells in part by targeting miR-150."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Cell Mol Med (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1111/jcmm.14281"}], "href": "https://doi.org/10.1111/jcmm.14281"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30895711"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30895711"}]}, {"type": "r", "ref": 18, "children": [{"type": "t", "text": "Shuai Wu, Jian Xie, Hao Shi, et al. "}, {"type": "b", "children": [{"type": "t", "text": "miR-492 promotes chemoresistance to CDDP and metastasis by targeting inhibiting DNMT3B and induces stemness in gastric cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Biosci Rep (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1042/BSR20194342"}], "href": "https://doi.org/10.1042/BSR20194342"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32065219"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32065219"}]}, {"type": "r", "ref": 19, "children": [{"type": "t", "text": "Luyi Ye, Chen Wang, Qixiu Yang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "[The role of miR-492 in the regulation of OK blood group antigen expression on red blood cells]."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2017)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3760/cma.j.issn.1003-9406.2017.05.013"}], "href": "https://doi.org/10.3760/cma.j.issn.1003-9406.2017.05.013"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "28981932"}], "href": "https://pubmed.ncbi.nlm.nih.gov/28981932"}]}]}]}
|
| Synonyms | MIRN492, HSA-MIR-492 |
| NCBI Gene ID | 574449 |
| API | |
| Download Associations | |
| Predicted Functions |
![]() |
| Co-expressed Genes |
![]() |
| Expression in Tissues and Cell Lines |
![]() |
MIR492 has 321 functional associations with biological entities spanning 6 categories (molecular profile, disease, phenotype or trait, functional term, phrase or reference, chemical, cell line, cell type or tissue, gene, protein or microRNA) extracted from 14 datasets.
Click the + buttons to view associations for MIR492 from the datasets below.
If available, associations are ranked by standardized value
| Dataset | Summary | |
|---|---|---|
| CCLE Cell Line Gene CNV Profiles | cell lines with high or low copy number of MIR492 gene relative to other cell lines from the CCLE Cell Line Gene CNV Profiles dataset. | |
| ChEA Transcription Factor Binding Site Profiles | transcription factor binding site profiles with transcription factor binding evidence at the promoter of MIR492 gene from the CHEA Transcription Factor Binding Site Profiles dataset. | |
| ChEA Transcription Factor Targets | transcription factors binding the promoter of MIR492 gene in low- or high-throughput transcription factor functional studies from the CHEA Transcription Factor Targets dataset. | |
| ENCODE Histone Modification Site Profiles | histone modification site profiles with high histone modification abundance at MIR492 gene from the ENCODE Histone Modification Site Profiles dataset. | |
| ENCODE Transcription Factor Binding Site Profiles | transcription factor binding site profiles with transcription factor binding evidence at the promoter of MIR492 gene from the ENCODE Transcription Factor Binding Site Profiles dataset. | |
| ENCODE Transcription Factor Targets | transcription factors binding the promoter of MIR492 gene in ChIP-seq datasets from the ENCODE Transcription Factor Targets dataset. | |
| GAD Gene-Disease Associations | diseases associated with MIR492 gene in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset. | |
| GeneRIF Biological Term Annotations | biological terms co-occuring with MIR492 gene in literature-supported statements describing functions of genes from the GeneRIF Biological Term Annotations dataset. | |
| GeneSigDB Published Gene Signatures | PubMedIDs of publications reporting gene signatures containing MIR492 from the GeneSigDB Published Gene Signatures dataset. | |
| GEO Signatures of Differentially Expressed Genes for Small Molecules | small molecule perturbations changing expression of MIR492 gene from the GEO Signatures of Differentially Expressed Genes for Small Molecules dataset. | |
| HuGE Navigator Gene-Phenotype Associations | phenotypes associated with MIR492 gene by text-mining GWAS publications from the HuGE Navigator Gene-Phenotype Associations dataset. | |
| JASPAR Predicted Transcription Factor Targets | transcription factors regulating expression of MIR492 gene predicted using known transcription factor binding site motifs from the JASPAR Predicted Transcription Factor Targets dataset. | |
| Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles | cell lines with high or low copy number of MIR492 gene relative to other cell lines from the Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles dataset. | |
| Roadmap Epigenomics Histone Modification Site Profiles | histone modification site profiles with high histone modification abundance at MIR492 gene from the Roadmap Epigenomics Histone Modification Site Profiles dataset. | |